Tag Archives: NICE

Big Pharma Welcomes Extension to England's Cancer Drug Fund, Critics Unconvinced

The Cancer Drugs Fund: Extension to 2016 By Leela Barham The Cancer Drugs Fund (CDF) in England covers the cost of cancer treatments either when the National Institute for Health and Care Excellence (NICE) has said ‘no’, or hasn’t yet come to a view.  It started with £50 million and is now £200million a year. […]
Posted in Europe, Global, Guest Blog, Op-Ed | Also tagged , , , , , | Leave a comment

The Little Orphan That Could: How Alexion is Going Global

Since the initial FDA approval of its flagship orphan drug Soliris in 2007, Alexion Pharmaceuticals has done well for itself as a small biotech firm that focuses on ultra-rare disease. So well in fact, that instead of partnering, the company has taken global expansion into its own hands. Apart from a pipeline that includes asfotase […]
Posted in Biotech, Global, Manufacturing, Market Access, Orphan Drugs, Strategy, Supply Chain | Also tagged , , , , , , , | Leave a comment

UK: NICE's Looming Value-Based Pricing Challenges

NICE role in VBP The National Institute for Health and Care Excellence (NICE) will have a vital role in the post 2014 value based pricing (VBP) world.  The Department of Health (DH) who still act as the sponsor organization for the agency, has set out in more detail just what value assessment by NICE will […]
Posted in Guest Blog, Op-Ed, pricing | Also tagged , , , , | Leave a comment

Those Amazing 'Gold Plated, Cadillac Care' Drug Programs

by Tom Norton Not too many years ago, while employed by one of America’s leading Rx manufacturers, I remember stepping up to a retail drug store counter to pick up a prescription.  As the pharmacist handed me my script, he said, “Wow.  I don’t know what kind of health insurance you have, but I have […]
Posted in FDA, Global, Guest Blog, healthcare, Legal, Market Access, pricing, Regulatory, Strategy | Also tagged , , , , , , , , , , , , , , , , , | Leave a comment

England's Latest Innovation Scorecard: A Patchy Picture

By Leela Barham. A common gripe from those in the pharma industry in England is that even when their products have been found to be cost effective by the National Institute for Health and Care Excellence (NICE) (not always easy to do these days), uptake in the NHS can be ‘low and slow’.  The latest […]
Posted in Europe, Global, Guest Blog, Regulatory | Also tagged , , , , | Leave a comment
  • Categories

  • Meta